Keyphrases
Randomized Trial
100%
Diabetes Incidence
100%
Women's Health Initiative
100%
Conjugated Equine Estrogens
100%
Estrogen Alone
80%
Diabetes
60%
Postmenopausal Women
40%
Insulin Resistance
40%
Clinical Trials
20%
Type 1 Diabetes Mellitus (T1DM)
20%
Type 2 Diabetes Mellitus (T2DM)
20%
Hysterectomy
20%
Cumulative Incidence
20%
Adverse Effects
20%
First Year
20%
Placebo
20%
Lipoproteins
20%
Insulin
20%
Primary Prevention
20%
Control Subjects
20%
Protective Effect
20%
Fasting Plasma Glucose
20%
Estrogen Plus Progestin
20%
Placebo Groups
20%
Between-group Difference
20%
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
20%
Glucose-insulin System
20%
Hazard Ratio
20%
6-year Follow-up
20%
Medroxyprogesterone
20%
Oral Hypoglycemic Agents
20%
Medicine and Dentistry
Diabetes
100%
Ethinylestradiol
100%
Womens Health
100%
Insulin Resistance
40%
Postmenopause
40%
Placebo
40%
Primary Prevention
20%
Study Participant
20%
Maturity Onset Diabetes of the Young
20%
Self Report
20%
Diabetes Mellitus
20%
Hysterectomy
20%
Cumulative Incidence
20%
Homeostatic Model Assessment
20%
Hazard Ratio
20%
Gestagen
20%
Antidiabetic Agent
20%
Clinical Trial
20%
Lipoprotein
20%
Adverse Effect
20%
Medroxyprogesterone
20%
Nursing and Health Professions
Premarin
100%
Ethinylestradiol
100%
Placebo
40%
Insulin Resistance
40%
Non Insulin Dependent Diabetes Mellitus
20%
Primary Prevention
20%
Study Participant
20%
Lipoprotein
20%
Hazard Ratio
20%
Homeostasis Model Assessment
20%
Self Report
20%
Antidiabetic Agent
20%
Gestagen
20%
Medroxyprogesterone
20%
Hysterectomy
20%
Diabetes Mellitus
20%
Pharmacology, Toxicology and Pharmaceutical Science
Conjugated Estrogen
100%
Ethinylestradiol
100%
Insulin Resistance
60%
Placebo
40%
Clinical Trial
20%
Lipoprotein
20%
Antidiabetic Agent
20%
Medroxyprogesterone
20%
Diabetes Mellitus
20%
Progestin
20%
Non Insulin Dependent Diabetes Mellitus
20%
Food Science
Insulin
100%
Lipoprotein
20%